糖尿病神经源性膀胱患者的尿流动力学变化及α-硫辛酸联合甲钴胺治疗的疗效被引量：21

导出

摘要目的观察糖尿病神经源性膀胱患者尿流动力学指标的变化及应用α-硫辛酸联合甲钴胺治疗的效果。方法糖尿病患者120例做尿流动力学检查,结果正常者为A组(53例),结果异常者按糖尿病病史分为两组,B组≤5年(32例),C组>5年(35例)。B、C组患者给予α-硫辛酸联合甲钴胺注射液治疗3周。治疗前后B超测定膀胱残余尿量(RUV)及做尿动力学检查。结果 B组RUV、最大尿流率时逼尿肌压力(Pdet)、膀胱初尿意容量(FS)较A组增加,最大尿流率(MFR)减少,C组与B组比较RUV、FS增加,MFR、Pdet减少;B组与C组治疗后RUV、FS均较治疗前减少,MFR增加,Pdet B组治疗后减少,C组治疗后增加,差异均有统计学意义(P<0.05)。B组患者症状阳性率37.5%,经治疗总有效率100%。C组症状阳性率85.7%,总有效率86.7%两组疗效相比差异有统计学意义。结论糖尿病神经源性膀胱患者起病隐袭,应早期行尿流动力学及膀胱残余尿检查;应用α-硫辛酸联合甲钴胺治疗疗效显著。

作者王丽娜周慧敏康岩郭玉卿刘璠

机构地区河北医科大学第一医院内分泌科

出处《广东医学》 CAS CSCD 北大核心 2014年第3期437-439,共3页 Guangdong Medical Journal

关键词糖尿病神经源性膀胱尿流动力学膀胱残余尿量 Α-硫辛酸

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1CHANG S,HYPOLITE J A,MOHANAN S,et al.Alteration of the PKC-mediated signaling pathway for smooth muscle contraction in obstruction -induced hypertrophy of the urinary bladder[J].Lab Invest,2009,89(7):823-832.
2DONN J,LEDGER A.An update on the treatment and management of diabetic peripheral neuropathy[J].Cannt J,2006,16(4):32-36.
3HEAD K A.Peripheral neuropathy:Pathogenic mechanisms and alternative therapies[J].Altern Med Rew,2006,11(4):294-329.
4常胜军.α-硫辛酸治疗糖尿病周围神经病变疗效观察[J].中国实用神经疾病杂志,2009,12(19):57-58. 被引量：27
5章晓燕,刘芳,贾伟平.α-硫辛酸与糖尿病周围神经病变[J].国外医学（内分泌学分册）,2005,25(4):262-264. 被引量：146
6KUWABARA S,NAKAZAWA R,AZUMA N,et al.Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients[J].Intern Med,1999,38(6):472-475.
7王述进,李俊枝,左红,周克斌,杨勇,赵留存.尿流动力学检查在糖尿病神经源性膀胱诊断中的意义[J].现代医学,2005,33(6):382-383. 被引量：6

二级参考文献22

1章晓燕,刘芳,贾伟平.α-硫辛酸与糖尿病周围神经病变[J].国外医学（内分泌学分册）,2005,25(4):262-264. 被引量：146
2Brownlee M.Biochemistry and molecular cell biology of diabetic complications[J].Nature,2001,414:813.
3Sekido H,Suzuki T,Jomori T,et al.Ruduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells[J].Biochem Biophys Res Commum,2004,320:241.
4Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001,414: 813-820.
5Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest,2001,108: 1341-1348.
6Du X,Matsumura T,Edelstein D,et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest, 2003, 112: 1049-1057.
7Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.Lancet, 2000,355: 253-259.
8Stevens MJ, Obrosova I, Cao X, et al. Effects of DL-alpha-lipic acid on peripheral nerve conduction, blood flow, energy metablism, and oxidative stress in experimental diabetic neuropathy. Diabetes, 2000, 49: 1006-1015.
9Androne L, Gavan NA, Veresiu IA, et al. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo, 2000,14: 327-330.
10El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertention, 2002,39: 303-307.